Amelotex

Quick links to important sections

Amelotex

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Amelotex

Quick Facts

Property Description
Active ingredient Meloxicam
Form Tablets, oral suspension, intravenous solution
Pharmacological class Nonsteroidal Anti-Inflammatory Drug (NSAID)
Common purpose Relief of signs of inflammation and pain
Origin Synthetic oxicam derivative

Defining Amelotex: Classification and Active Substance

Amelotex is a specific pharmaceutical brand whose active component is Meloxicam, a substance classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). The active substance, Meloxicam, is structurally a synthetic oxicam derivative and a single-ingredient compound belonging to the enolic acid group. This classification means the medication is fundamentally designed to reduce the body's inflammatory response and associated discomfort. Amelotex is clinically recognized for its long half-life, a pharmacokinetic property that often supports once-daily dosing for conditions requiring sustained action.

Mechanism and General Therapeutic Purpose

Meloxicam's foundational mechanism involves the inhibition of prostaglandin synthetase, which blocks the formation of chemical mediators responsible for pain and inflammation. It is primarily characterized as a preferential inhibitor of cyclo-oxygenase-2 (COX-2), meaning it targets the enzyme largely induced during inflammatory processes. This specific, targeted activity provides the drug with its potent anti-inflammatory and analgesic (pain-relieving) properties. The overall therapeutic purpose is achieved by mitigating swelling and easing the discomfort caused by systemic or localized inflammatory processes.

Available Pharmaceutical Forms and Composition

Amelotex is supplied in several distinct dosage forms to accommodate various patient needs and routes of administration. These include oral preparations, such as tablets and oral suspension, for enteral administration. A specialized solution for intravenous administration (IV) is also available for use in controlled clinical settings. The composition of all forms centers on the active substance Meloxicam combined with standard pharmaceutical excipients necessary for product stability and to create the appropriate delivery vehicle.

What side effects are possible with Amelotex?

Possible side effects and safety information

The official safety profile for Amelotex, whose active substance is Meloxicam, is defined by regulatory agencies based on categorized adverse reactions and specific systemic risks associated with the NSAID class.

Regulatory Classification of Adverse Reactions

Adverse effects are formally categorized by incidence, ranging from Very Common (ge 1/10) and Common (ge 1/100 to < 1/10), to Uncommon, Rare, and Very Rare events, based on regulatory standards. The effects are also grouped by System-Organ Class (SOC), including the Gastrointestinal, Cardiovascular, Renal and Urinary, Hepatobiliary, and Nervous System Disorders.

Classification Example Effects (High-Level Grouping)
Common Headache, dizziness, dyspepsia, nausea, vomiting, abdominal pain
Uncommon Anemia, edema, vertigo, hypertension, increased liver enzymes
Rare/Very Rare Gastrointestinal ulceration, severe cutaneous reactions, acute renal failure, hepatic failure

Serious Adverse Reactions and Safety Constraints

Regulatory documentation highlights the potential for Serious Cardiovascular Thrombotic Events, including myocardial infarction and stroke, and Serious Gastrointestinal Adverse Events, such as bleeding, ulceration, and perforation, which can be fatal. These risks are noted to potentially increase with the duration of use and may be higher at elevated dosages.

Specific safety considerations are defined for certain patient populations. The official constraints restrict use during the third trimester of pregnancy and often limit use in older adults (due to increased risk of serious events) or in individuals with advanced kidney or hepatic impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Amelotex (Meloxicam) overdose details the spectrum of risks and the required emergency actions, strictly based on government-authorized prescribing information.

Documented Manifestations

Initial signs of overdose, which are generally reversible with symptomatic and supportive care, include gastrointestinal distress such as nausea, vomiting, epigastric pain, and central nervous system effects like lethargy and drowsiness. Gastrointestinal bleeding is also a noted potential complication.

Severe and Life-Threatening Outcomes

Urgent medical intervention must be sought for patients who are severely symptomatic or have experienced a substantial overdose. Officially documented severe outcomes of poisoning include acute renal failure, hepatic dysfunction, respiratory depression, coma, convulsions, and serious cardiovascular events such as cardiovascular collapse and cardiac arrest. Anaphylactoid reactions may also occur.

Official Emergency Response

Management must prioritize symptomatic and supportive care, as no specific antidote is known. Official instructions indicate that activated charcoal is recommended for administration 1 to 2 hours after overdose, and may be repeated for severely symptomatic cases. The administration of cholestyramine may be useful to accelerate the drug's clearance. Procedures like forced diuresis or hemodialysis are generally considered ineffective due to the drug’s high protein binding.

Therapeutic Uses of Amelotex

What Amelotex Treats: Main Uses and Benefits

Amelotex is relevant for symptomatic management in conditions characterized by periods of heightened symptoms, such as the chronic inflammatory joint diseases Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis. It is commonly used across these conditions to address symptoms related to inflammatory or irritative states and physical discomfort.

This medication assists with managing symptom clusters that may become intense or disruptive, particularly pain arising from musculoskeletal structures, including episodes of acute low back discomfort. It is also considered relevant in clinical settings involving acute or unstable symptom patterns, such as managing post-procedural discomfort or providing specialized symptomatic assistance for pediatric patients aged two years and older with Juvenile Idiopathic Arthritis (JIA).

By helping to reduce associated functional symptoms like joint stiffness and tenderness, Amelotex is commonly used to help with supporting patients during episodes of heightened discomfort. The intent is to contribute to easing the overall symptom load during symptomatic periods, which may assist with maintaining functional stability.

Quick Fact: Relevant for Managing Symptoms Related to Inflammatory States

Eligibility and Restrictions for Use

Who Can and Cannot Use Amelotex? (Official Regulatory Information)

Official regulatory documents define strict population eligibility for Amelotex (Meloxicam) based on age, pre-existing conditions, and physiological status.

Eligibility Scope

Category Regulatory Status Status Details
Adults and Adolescents Allowed Generally permitted for use in adults and adolescents aged 16 years and over for standard indications (EMA/SmPC).
Pediatric Patients Allowed/Restricted Approved for patients 2 years of age and older specifically for Juvenile Idiopathic Arthritis (US FDA). Use is generally contraindicated for children under 16 for adult tablet forms (EU/UK).
Pregnancy Contraindicated/Limited Contraindicated from approximately 30 weeks of gestation onward. Use is limited between 20 and 30 weeks of gestation (FDA).
Lactation Not Recommended Use while breastfeeding is generally not recommended, as excretion in human milk is not fully known.

Populations for Whom Use is Contraindicated

Amelotex is contraindicated and must not be used in individuals with the following official exclusions:

  • Hypersensitivity: Known allergy to meloxicam or a history of allergic reactions (asthma, angioedema, urticaria) after taking aspirin or other NSAIDs.
  • Surgery: For the treatment of pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.
  • GI History: Active or a history of recurrent peptic ulceration or hemorrhage.
  • Organ Failure: Patients with severe heart failure, severely impaired liver function, or non-dialyzed severe renal failure.

Condition-Specific Eligibility

  • Patients with end-stage renal failure who are on hemodialysis are subject to an official maximum daily dose restriction.
  • Elderly, frail, or weakened individuals require careful consideration due to their increased risk for adverse reactions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines officially documented interactions for Meloxicam (Amelotex) as stated in regulatory prescribing information.

Contraindicated Combinations

Meloxicam should not be used concomitantly with other Non-Steroidal Anti-inflammatory Drugs (NSAIDs) or analgesic doses of aspirin, as this combination significantly increases the risk of serious gastrointestinal adverse events. Use is also contraindicated for managing pain following Coronary Artery Bypass Graft (CABG) surgery.

Clinically Significant Drug Interactions

Interacting Product Category Documented Effect / Rationale
Anticoagulants/Antiplatelet Agents (e.g., Warfarin) Increased risk of bleeding due to additive effects on hemostasis.
Lithium / Methotrexate Meloxicam may increase plasma concentrations and toxicity of Lithium and Methotrexate due to reduced renal clearance.
Diuretics / Antihypertensives May reduce the therapeutic effect of these agents; concurrent use with ACE Inhibitors or ARBs can increase the risk of renal function deterioration, particularly in volume-depleted or elderly patients.
Cholestyramine Accelerates the elimination and clearance of Meloxicam by binding it in the gastrointestinal tract.

Other Considerations

The product's metabolism involves the CYP2C9 enzyme, meaning medications that strongly inhibit this enzyme may increase Meloxicam plasma levels. No specific food interactions are consistently documented, though the drug is often advised to be taken with food to minimize digestive upset.

Mechanism of Action

Amelotex, containing the active molecule meloxicam, functions as a nonsteroidal anti-inflammatory drug (NSAID) primarily through enzyme inhibition. Its main biological targets are the cyclooxygenase (COX) isoforms, specifically exhibiting preferential inhibitor activity toward cyclooxygenase-2 (COX-2) over cyclooxygenase-1 (COX-1). The COX-2 enzyme is an inducible component expressed at cellular sites of localized physiological response.

Molecularly, this preferential inhibition blocks the active site of the COX-2 enzyme, thereby preventing the conversion of arachidonic acid into prostaglandin H2. This interruption in the upstream metabolic pathway results in a pronounced intracellular reduction in the synthesis and subsequent release of pro-inflammatory prostaglandins. System-level physiological consequences include modulation of local mediator concentrations that influence tissue-level responses to various stimuli, particularly in the peripheral circulation and synovial compartments, where the drug accumulates.

Dosage and Administration Information

Amelotex (meloxicam) is administered via two official routes, and its use is guided by established dosing and frequency schedules. In alignment with clinical standards for all Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), the treatment must employ the lowest effective dose for the shortest duration possible to meet individual patient goals.

Approved Administration Routes

The medication is approved for oral intake (as tablets or suspension) and for intravenous (IV) injection in a controlled clinical setting.

Standard Dosing and Frequency

The approved regimen for adults is once daily (qDay). Oral dosing for chronic conditions, such as Osteoarthritis or Rheumatoid Arthritis, typically starts at 7.5 mg. The dose may be adjusted to a maximum daily limit of 15 mg based on response. The IV solution is administered as a single dose of 30 mg once daily for pain management.

Population/Route Starting Dose Maximum Daily Dose Frequency
Adult Oral Dose 7.5 mg 15 mg Once Daily
Adult IV Dose 30 mg 30 mg Once Daily
Pediatric JIA 0.125 mg/kg 7.5 mg Once Daily

Administration Conditions and Adjustments

Oral forms (tablets and suspension) may be taken with or without food. The oral suspension should be shaken gently before use. For IV administration, the injection must be given as an intravenous bolus over 15 seconds, and patients must be well-hydrated beforehand to reduce potential renal risks. A lower maximum dose of 7.5 mg is advised for patients on hemodialysis. Pediatric dosing for Juvenile Idiopathic Arthritis (JIA) is based on body weight, with a maximum of 7.5 mg per day.

Recent Clinical Evidence

This section provides an overview of the official research structure and findings for Amelotex (Meloxicam), as reported in clinical trials and regulatory documents. This summary focuses on the types of evidence that exist, what was measured in those studies, and where research remains limited.


Evidence for Chronic Inflammatory Joint Diseases

Research for clinical situations related to Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Ankylosing Spondylitis (AS) relies on large-scale randomized controlled trials (RCTs) and systematic reviews. These studies explored how symptoms change in conditions characterized by fluctuating manifestations. Researchers examined outcomes related to physical discomfort, such as standardized pain intensity scores, and outcomes reflecting daily functioning, comparing the medication against both placebo and various other established anti-inflammatory agents.

While the evidence contributes to the broader landscape for short-term changes in symptoms, long-term outcomes regarding the durability of symptom control and functional stability beyond one year are not as well characterized by high-quality RCTs. Comparative evidence is also lacking against all newer classes of similar medicines.


Evidence for Acute Pain Management

The evidence for use in clinical contexts involving acute pain is primarily derived from randomized, double-blind, placebo-controlled trials, often conducted following surgical procedures. These studies explored short-term symptom changes, monitoring outcomes linked to inflammatory states over observation windows of 24 to 48 hours. The established evidence is specific to the intravenous (IV) route of administration; corresponding short-term data for oral forms in this acute context are limited.


Evidence in Special Populations and Uncertainties

The medication was evaluated in specific controlled clinical trials for pediatric patients with Juvenile Idiopathic Arthritis (JIA). For older adults, specific subgroup findings are uncertain due to a lack of dedicated, large-scale studies. Overall, data for certain specialized groups remain insufficient, and research does not determine whether an individual will respond similarly to the group patterns observed in these studies.

Frequently Asked Questions (FAQ)

Common questions about Amelotex (FAQ)

Q: Can Amelotex be used for back pain?

Amelotex (meloxicam) is officially approved for treating the symptoms of conditions such as Osteoarthritis (OA) and Ankylosing Spondylitis (AS).

These conditions commonly involve discomfort and inflammation in the joints of the spine and other parts of the back. The official labeling defines use based on the diagnosed medical condition.

Q: How long can a person typically use Amelotex?

Official guidelines state that this type of medication should be used for the shortest effective duration possible to minimize the risk of serious side effects.

While Amelotex is approved for the management of chronic conditions, the total duration should be determined by a healthcare provider.

Q: Can Amelotex cause weight gain?

Official prescribing information lists edema, or fluid retention, as an uncommon side effect of Amelotex.

Fluid retention can sometimes be associated with a change in body weight due to the accumulation of excess fluid. This information is provided for awareness and is not a substitute for professional medical guidance.

Q: How long does Amelotex stay in your system?

The active ingredient, meloxicam, has a long plasma elimination half-life of approximately 20 hours.

This property means the drug stays in the body for an extended period, which supports the official once-daily frequency of use.

Q: Why do some people say Amelotex is easier on the stomach than other drugs?

Regulatory documents describe Amelotex as a nonsteroidal anti-inflammatory drug (NSAID) with a preferential inhibitory activity toward COX-2.

This characteristic is notable because the inhibition of the COX-1 enzyme is often linked to irritation and potential injury to the stomach lining. This selective action is generally viewed as favorable to the stomach lining.

Q: Are there any official restrictions on driving while using Amelotex?

Official safety information lists side effects such as dizziness and somnolence (drowsiness) as having been reported with use.

Patients are cautioned that these effects may impair the ability to drive or operate machinery, and caution should be exercised.

Q: Are there studies comparing the effectiveness of Amelotex in different types of arthritis?

Clinical trials were conducted separately for its approved chronic indications, including Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Ankylosing Spondylitis (AS).

While these studies established its effect against placebo and other treatments, the official evidence typically examines effectiveness within each specific condition rather than comparing outcomes across them.

Q: How quickly does Amelotex usually start to work?

According to information from health authorities, meloxicam has a delayed onset for its full anti-inflammatory effect due to its long half-life.

It may take several days of consistent use before the full, stable therapeutic benefit is achieved for chronic arthritis conditions.

Q: Is Amelotex available without a prescription in some countries?

In major regulatory markets such as the United States, the active ingredient meloxicam (Amelotex) is available by prescription only (Rx status).

Its use requires the oversight and authorization of a healthcare professional.

Q: Can Amelotex make you feel sleepy or tired?

Official adverse reaction reports list somnolence (drowsiness) as a reported side effect of meloxicam use.

Drowsiness is listed among the common adverse reactions.

Q: What happens if I miss taking an amount of Amelotex?

General patient instructions advise taking the missed amount as soon as it is remembered. However, if it is nearly time for the next scheduled amount, the official guidance is to skip the missed amount and stick to the regular schedule.

Taking two amounts simultaneously is generally not advised.

Q: Are there any known issues with taking Amelotex and alcohol?

Official safety information advises that taking meloxicam while consuming alcohol is generally not recommended.

Concurrent use may increase the risk of serious side effects, specifically irritation and bleeding in the gastrointestinal tract.

Q: Does Amelotex interact with common vitamins or supplements?

While official regulatory documents list specific interactions with certain prescription medications, they do not list specific vitamins or supplements.

It is recommended that a healthcare provider be informed about all supplements and over-the-counter products being used.

Q: Is Amelotex considered a controlled substance?

No, meloxicam (Amelotex) is classified as a nonsteroidal anti-inflammatory drug (NSAID).

It is not listed as a controlled substance under the U.S. Controlled Substances Act or similar international regulatory schedules.

Q: What should I do if I think Amelotex is not working for me?

The dosage range is officially defined by health authorities.

Official patient counseling notes that the amount can be adjusted based on individual response, and such decisions are typically made by the prescribing healthcare provider.

Q: Is Amelotex used for gout or just for arthritis?

Amelotex is officially approved for treating various forms of arthritis, including Osteoarthritis and Rheumatoid Arthritis.

While NSAIDs are widely used for acute gout attacks, meloxicam is not specifically listed as an FDA-approved indication for gout on all prescribing labels.

Q: Can Amelotex be crushed or split?

Official patient instructions advise that the standard Amelotex tablet formulation should typically be swallowed whole.

Unless a specific form of the drug is designed to be split or dissolved, crushing or splitting the tablets is generally not recommended in official guidance.

Q: Is there a specific time of day best for taking Amelotex?

Amelotex is designed for once-daily administration.

Regulatory documents do not specify a time of day (such as morning or evening) as being superior, but official guidance suggests maintaining consistency with the time you choose. Taking it with food is often advised to help minimize stomach upset.

Q: Are there generic versions of Amelotex available?

Yes, Amelotex is a brand name for the active ingredient meloxicam.

Meloxicam is widely available in authorized generic forms that regulatory agencies have deemed to be equivalent to the brand-name product.

Q: Can Amelotex interact with antidepressant medicines?

Official drug interaction warnings note that NSAIDs can interact with certain types of antidepressants, such as Selective Serotonin Reuptake Inhibitors (SSRIs).

This combination is officially noted as possibly increasing the risk of serious gastrointestinal bleeding.

Q: Is it possible to take Amelotex with Tylenol (acetaminophen)?

Regulatory documentation does not report a significant direct drug-to-drug interaction between meloxicam and acetaminophen (Tylenol).

The two medications may often be used together, but any dual-use typically requires review by a healthcare provider.

Q: Does Amelotex affect fertility?

Official information states that meloxicam, like many other NSAIDs, may delay or prevent ovulation in women who are attempting to become pregnant.

This effect is described as being reversible once the medication is stopped.

Q: What does 'contraindication' mean regarding Amelotex?

A contraindication is an official statement from health authorities indicating that the medication must not be used by a patient in a specific circumstance.

Examples of contraindications for Amelotex include a known allergy to NSAIDs or use for pain management following Coronary Artery Bypass Graft (CABG) surgery.

Q: Is it possible to overdose on Amelotex?

Yes, regulatory documents address the possibility of overdose with meloxicam.

In the event of an overdose, symptoms like lethargy and drowsiness are typically reported, and severe complications can include acute renal failure, hepatic failure, and cardiac arrest.

Q: Does Amelotex contain gluten?

The inactive ingredients (excipients) used in Amelotex formulations are listed in official product information.

While the label may not explicitly carry a 'gluten-free' claim, many common formulations utilize excipients, such as microcrystalline cellulose and maize starch, that are not derived from gluten sources.

Q: What are the official guidelines about stopping Amelotex?

Official guidance primarily emphasizes that the medication should be taken for the shortest effective duration.

Regulatory documents do not prescribe a specific method for discontinuing use, as the decision to stop taking the medication is typically made by the prescribing healthcare provider.

Q: Is there a physical difference between the tablet and the oral suspension forms?

Amelotex is available as a solid tablet and a liquid oral suspension.

Official labeling describes the suspension as a yellow, viscous liquid, and the tablets are typically pale yellow. The liquid form requires careful shaking before use to ensure the active ingredient is evenly distributed.

Q: Does using Amelotex reduce fever?

Meloxicam is classified as an NSAID, a class of drugs with properties that can mask symptoms like fever.

Health authorities caution that this fever-reducing ability can interfere with the diagnosis of an underlying infection.

How should Amelotex be stored and disposed of?

Storage Conditions

Amelotex (meloxicam) tablets and oral suspension must be stored at Controlled Room Temperature, specifically between 20°C and 25°C (68°F and 77°F), with permitted excursions up to 30°C (86°F).

The product must be protected from excessive heat and moisture to maintain stability. Orally Disintegrating Tablets (ODT) are required to remain in their original package until the time of use.

Child Safety and Handling

As mandated by regulatory documents, all forms of the medication must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Amelotex should be disposed of via a drug take-back program if one is available locally. If no program exists, the product should be mixed with an undesirable substance (such as dirt or coffee grounds) and placed in a sealed container for disposal in the household trash. Do not flush this medicine down the toilet or pour it into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Amelotex found in:

A-Z Index: